📰 Clinical Development Program News
Page 9 - Clinical Development Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Clinical Development Program. Real-time updates on events, politics, business and more.
May 16, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
May 9, 2022
- Final Dataset from ARTISTRY-1 Clinical Trial to be Featured in an Oral Presentation - - Trial-in-Progress Posters From ARTISTRY-3, ARTISTRY-6 and ARTISTRY-7 Clinical Trials to be Presented
May 9, 2022
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the acceptance of four abstracts related to nemvaleukin alfa (nemvaleukin), the companys novel,...
May 5, 2022
Approval broadens indication for Daiichi Sankyo and AstraZeneca’s ENHERTU to earlier use in metastatic breast cancerBased on groundbreaking DESTINY-Breast03 results showing ENHERTU reduced the risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1)TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)...
May 5, 2022
Press release content from Business Wire. The AP news staff was not involved in its creation.
March 9, 2022
Chemomab Therapeutics Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update - read this article along with other careers information, tips and advice on BioSpace
January 5, 2022
“Noxopharm is a unique company. I feel very honoured to be chosen as its next CEO and I am excited to lead the company through its next...
January 5, 2022
“Noxopharm is a unique company. I feel very honoured to be chosen as its next CEO and I am excited to lead the company through its next...
December 23, 2021
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the first patient was dosed in the global DESTINY-Lung04 phase 3 trial evaluating the efficacy and safety of ENHERTU (trastuzumab
December 9, 2021
DESTINY-Breast03 data presented at SABCS 2021 showed Daiichi Sankyo and AstraZeneca's ENHERTU demonstrated a similar benefit in patient subgroups, including those with stable brain metastases, compared